Shumei Man, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, and colleagues examined whether the shorter door to needle times with intravenous tPA for acute ischemic stroke is associated with improved long-term outcomes.
The study included Medicare beneficiaries aged 65 years or older (n=61,426) with acute ischemic stroke and were treated with IV tPA within 4.5 hours from the time they were last known to be well at Get With The Guidelines–Stroke participating hospitals between January 1, 2006, and December 31, 2016, with 1-year follow-up through December 31, 2017.
In this study, the median door-to-needle time was 65 minutes.
The primary outcomes were 1-year all-cause mortality, all-cause readmission, and the composite of all-cause mortality or readmission.
Key findings of the study include:
- The 48 666 patients (79.2%) who were treated with tPA and had door-to-needle times of longer than 45 minutes, compared with those treated within 45 minutes, had significantly higher all-cause mortality (35.0% vs 30.8%, respectively), higher all-cause readmission (40.8% vs 38.4%), and higher all-cause mortality or readmission (56.0% vs 52.1%).
- The 34 367 patients (55.9%) who were treated with tPA and had door-to-needle times of longer than 60 minutes, compared with those treated within 60 minutes, had significantly higher all-cause mortality (35.8% vs 32.1%, respectively), higher all-cause readmission (41.3% vs 39.1%), and higher all-cause mortality or readmission (56.8% vs 53.1%).
- Every 15-minute increase in door-to-needle times was significantly associated with higher all-cause mortality within 90 minutes after hospital arrival, but not after 90 minutes, higher all-cause readmission, and higher all-cause mortality or readmission.
"Among patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasminogen activator, shorter door-to-needle times were associated with lower all-cause mortality and lower all-cause readmission at 1 year. These findings support efforts to shorten time to thrombolytic therapy," concluded the authors.
The study, "Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke," is published in the journal JAMA.
DOI: 10.1001/jama.2020.5697
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.